TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06413108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F
Study: NCT06413108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F
Study: NCT06574074

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gain-Life (Give informAtIoN to transform Life)
Description: The Gain Life intervention comprises four components: (i) information about depression, (ii) awareness of available services, (iii) stigma reduction through dispelling myths and facts about depression, and (iv) a life transformation story. The first module aims to raise awareness about depression, with a particular focus on its causes, manifestations, and the potential negative consequences of untreated depression. The second component includes the types of services offered, costs, distance to service providers, and operating hours. The third component address stigma and misconceptions surrounding depression by addressing the root causes of stigma, dispelling myths, and providing accurate information about depression. The final module of the Gain Life intervention features recovery stories of individuals who have overcome depression. This module includes two 8-minute video stories of individuals who successfully recovered from depression.
Study: NCT06541457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7249 injection
Description: 6 subjects for HRS-7249 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7249 injection
Description: 6 subjects for HRS-7249 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7249 injection
Description: 6 subjects for HRS-7249 injection
Study: NCT06413108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB31F
Description: transmission-blocking monoclonal antibody TB31F

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as control (placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as control (placebo)
Study: NCT06541457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7249 injection
Description: 6 subjects for HRS-7249 injection
Study: NCT06413108

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as control (placebo)
Study: NCT06541457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7249 injection
Description: 6 subjects for HRS-7249 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7249 injection
Description: 6 subjects for HRS-7249 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 subjects for placebo
Study: NCT06413108

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as control (placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as control (placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as control (placebo)
Study: NCT06541457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 subjects for placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 subjects for placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 subjects for placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 subjects for placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 subjects for placebo
Study: NCT06049563

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic MRI
Description: MRI scan of the upper abdomen performed with the low-field 0.4T MRI system.
Study: NCT06509087

Intervention type: PROCEDURE
Intervention: Transarterial microembolization (TAME)
Description: TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.

Intervention type: PROCEDURE
Intervention: Transarterial microembolization (TAME)
Description: TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
Study: NCT05661539

Intervention type: DEVICE
Intervention: Transvaginal Ultrasonography
Description: The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.

Intervention type: DEVICE
Intervention: Transvaginal Ultrasonography
Description: The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.
Study: NCT06451172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASO
Description: Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
Study: NCT06532214

Intervention type: DIAGNOSTIC_TEST
Intervention: International Study Group for Liver Surgery (ISGLS)
Description: According to the ISGLS criteria, the patient was judged to have liver failure and further analysis
Study: NCT05314439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION904
Description: ION904 will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study: NCT04728295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate 4000
Description: Exablate Pallidothalamic Tractotomy
Study: NCT05974527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing dexmedetomidine (BXCL501)
Description: Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
Study: NCT05123508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940nm and BBL treatment
Description: 2940nm and BBL treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-treatment side (Control)
Description: No treatment
Study: NCT05981443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: Use of Dermabond to close surgical incisions instead of non-absorbable sutures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Absorbable Sutures
Description: Use of conventional non-absorbable sutures to close surgical incisions
Study: NCT05661539

Intervention type: DEVICE
Intervention: Transvaginal Ultrasonography
Description: The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.
Study: NCT05881564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood use for priming cardiopulmonary bypass circuit
Description: one arm will have the cardiopulmonary bypass circuit primed with blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clear prime for cardiopulmonary bypass
Description: this arm will not have bypass circuit primed with blood
Study: NCT05770141

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laser hemorrhoidoplasty
Description: A skin incision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open surgical hemorrhoidectomy
Description: The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
Study: NCT04582539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 will be administered once daily.
Study: NCT06574152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM treatment
Description: Immediately after the apical microsurgery, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, North Carolina, USA), with an 8 mm tip diameter . The laser tip will be placed following the outline of the incision flap in a contact mode . The power output of the laser will be 50 milliwatt (mW) and verified by a Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PBM sham treatment
Description: Immediately after the apical microsurgery, sham therapy will be performed without activating the laser.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EMS
Description: Patients will be anesthetized. All surgeries will be performed using a surgical microscope. After reflection of a mucoperiosteal flap, osteotomies will be performed to access the root apices and apical lesions. Root apices will be resected at 3 mm, and the pathological tissue curetted out. Next, root-end preparations will be made with ultrasonic tips and filled with calcium silicate-based materials. Methylene blue dye will be used for inspection after root-end resection before the root-end preparation and filling. After cleaning the osseous crypt, the wound margins will be reapproximated with 5-0 single interrupted sutures. A gauze will be placed for 30 minutes for wound compression. Sutures will be removed seven days postoperatively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: Patients will be anesthetized. All surgeries will be performed using a surgical microscope. After reflection of a mucoperiosteal flap, osteotomies will be performed to access the root apices and apical lesions. Root apices will be resected at 3 mm, and the pathological tissue curetted out. Next, root-end preparations will be made with ultrasonic tips and filled with calcium silicate-based materials. Methylene blue dye will be used for inspection after root-end resection before the root-end preparation and filling. After cleaning the osseous crypt, the wound margins will be reapproximated with 5-0 single interrupted sutures. A gauze will be placed for 30 minutes for wound compression. Sutures will be removed seven days postoperatively
Study: NCT06574685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Twinkle Eyez Supplementation
Description: The intervention supplement consisted of marigold extract, zeaxanthin, elderberry extract, bilberry extract, lycopene extract, multivitamin, silicon dioxide, inulin, and dextrose monohydrate, all in powder form and packaged in individual sachets (Twinkle Eyez™; Xmegami, Selangor, Malaysia). Each sachet contained 4.6 mg of lutein and zeaxanthin and 15.4 mg of elderberry extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo supplement was identical in composition but excluded the active ingredients.
Study: NCT06576180

Intervention type: DRUG
Intervention: Carboplatin（ neoadjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Intervention: Paclitaxel （neoadjuvant）
Description: Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Intervention: Anti-PD-1 Drugs
Description: Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Standard of care

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Standard of care
Study: NCT05219591

Intervention type: DEVICE
Group type: OTHER
Intervention: EPR
Description: application of EPR technology during CPAP treatment

Intervention type: DEVICE
Group type: OTHER
Intervention: EPR
Description: application of EPR technology during CPAP treatment
Study: NCT05510479

Intervention type: OTHER
Intervention: Software as medical device
Description: At home measurements of visual acuity through a mobile app
Study: NCT06438029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education group
Description: the students in the experimental group will be trained on disaster and disaster response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: the students in the experimental group will be trained on disaster and disaster response
Study: NCT05203341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT05206006

Intervention type: OTHER
Group type: OTHER
Intervention: routine care
Description: The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
Study: NCT05203341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1065845
Description: NBI-1065845 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1065845
Description: NBI-1065845 tablets
Study: NCT05457608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
Study: NCT05206006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Decision support app (CDSA)
Description: Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice. This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
Study: NCT04901429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy
Description: Truncal vagotomy will be performed in 50% of patients during other routine procedure.
Study: NCT04826354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin and Ezetimibe
Description: Rosuvastatin Versus Rosuvastatin plus Ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study: NCT05484674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deroofing and laser
Description: Deroofing and laser to axilla
Study: NCT04874870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]
Description: 1 injection of 0.58mg will be injected into applicable cord.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Xiaflex + Hand-Based Custom Orthosis
Description: 1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
Study: NCT06382350

Intervention type: DEVICE
Intervention: MiniMed 780 G
Description: none, observational study
Study: NCT05538624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-001 (Dose Escalation Phase)
Description: One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-001 (Dose Expansion Phase)
Description: The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
Study: NCT06356064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Radİal ESWT and focus ESWT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Radİal ESWT and focus ESWT
Study: NCT05224050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Smoking Cessation
Description: Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Description: Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
Study: NCT05027451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXT-m200
Description: Anti-methamphetamine chimeric monoclonal antibody (mAb)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT06573463

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefabricated band and loop
Description: Prefabricated space maintainer requires only one visit as it fits into the patient's mouth at the clinic without needing the dental lab. It comes in a kit with different band sizes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Band and loop
Description: Conventional band and loop is the most widely used space maintainer, It shows high success rate and good patient compliance, but needs more than one visit due to the laboratory work.
Study: NCT06224647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Transdiagnostic Emotion Regulation Intervention
Description: The intervention aims to provide a tailored and engaging way for users to manage and comprehend their emotional well-being.~It consist of 5 components:~1. Daily tracking of emotions~2. A suite of exercises placed in six categories facilitating adaptive emotion regulation skills (i.e., upregulation of positive effect, self-compassion, cognitive defusion and cognitive restructuring, mindfulness, breathing techniques),~3. A self-assessment module where users can complete surveys evaluating their states (e.g., wellbeing) and traits (e.g., perfectionistic tendencies),~4. A personal toolkit area (i.e., each exercise is represented by an object commonly found in a student's room. Users can collect objects of favoured exercises in the virtual ROOM, enabling them quick access to exercises they liked / found helpful),~5. A recommendation system linking users to the content based on their specific needs or preferences
Study: NCT05587595

Intervention type: OTHER
Intervention: questionnaires & data collection
Description: questionnaires

Intervention type: OTHER
Intervention: questionnaires & data collection
Description: questionnaires
Study: NCT04200989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut allergen
Description: Intralymphatic immunotherapy injections.
Study: NCT04471194

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampling HPV test
Description: Tests for human papillomavirus from cervical cell sample

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test
Description: Tests for human hemoglobin from blood in fecal samples
Study: NCT05530434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transpulmonary pressure guided positive end expiratory pressure
Description: Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard positive end expiratory pressure
Description: Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
Study: NCT05630833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05841680

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SSI Module
Description: Single Session Intervention (SSI) module for youth with anxiety disorders and their parents. The SSI module will include psychoeducation on the cognitive behavioral conceptualization of anxiety, introduction to self-regulation strategies to manage physiological manifestations of anxiety, and cognitive restructuring of anxiogenic thoughts. The SSI module will also involve parents and present strategies on how parents can support their children in managing anxious feelings and thoughts.